Health Care·Pharmaceuticals·$49.1B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.53 | N/A | +3.33% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.53 | N/A | +3.33% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management conveyed a positive outlook on product demand. They emphasized their commitment to innovation and growth in the animal health sector.
Management highlighted strong demand for animal health products.
They expressed confidence in their market position despite competitive pressures.
Zoetis reported a better-than-expected EPS, which contributed to a 5.9% increase in stock price. The positive earnings surprise reflects strong demand for their products, although no revenue figures were disclosed. Investors may view this as a sign of resilience in the animal health market.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
SBA COMMUNICATIONS C Class A REIT
May 1, 2017